Form 4: Stoke Therapeutics CEO Sells Shares to Cover Tax Obligations

Stoke Therapeutics CEO, Edward M. Kaye, sold 6,170 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Summary

• Edward M. Kaye, CEO of Stoke Therapeutics, sold 6,170 shares of common stock on December 6, 2024.
• The sale was mandated by the company to cover tax withholding liabilities associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $12.7775.
• The actual sale prices ranged from $11.93 to $13.46 per share.
• Following the transaction, Mr. Kaye beneficially owns 68,671 shares of Stoke Therapeutics stock.

Sentiment

Score: 5

Explanation: This is a routine transaction for tax purposes and does not indicate a change in the company's outlook or the CEO's confidence in the company.

Industry Context

This is a routine transaction for executives who receive stock-based compensation, and it is common for them to sell shares to cover tax liabilities.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• The price range of $11.93 to $13.46 is within the typical trading range for a company like Stoke Therapeutics.

Stakeholder Impact

• The sale of shares by the CEO has a minimal impact on shareholders as it is a routine transaction for tax purposes.
• The sale does not indicate any change in the company's performance or outlook.

Key Dates

Keywords

Stoke Therapeutics, Edward M. Kaye, stock sale, insider trading, tax withholding, restricted stock units, STOK